Meeting Report: American Urological Association (AUA) 2023 Annual Meeting


Key Points

  • The latest AUA meeting was held in Chicago from April 28 through May 1. 
  • There were 15 abstracts that may be of interest to the focused ultrasound community. 
  • Profound Medical and EDAP each issued a press release about the meeting. 
American Urological Association 2023 Annual Meeting held in Chicago from April 28 through May 1

The 2023 American Urological Association (AUA) Annual Meeting was held in Chicago from April 28 through May 1. AUA offers the latest technology and education for urologists, oncologists, osteopaths, urology residents, researchers, advanced practice professionals, educators, technicians, nurses, medical assistants, medical students, and other health care professionals. 

In the meeting’s first plenary session, Art Rastinehead, DO, delivered AUA’s 2023 State-of-the-Art Lecture, titled “The Future of Interventional Urology: The Next Paradigm Shift.” Dr. Rastinhead predicted that the future lies in focal therapy for prostate cancer, especially as the technology improves to identify significant lesions, guide the therapy, and evaluate for therapy success in real time. He also predicted that urologists would use modular operating rooms for 3D navigation/fusion, cross-sectional imaging, patient data tracking, and radiation safety to treat kidney stones, renal mass biopsies, and tube placement. Changes in urology training pathways may soon include imaging and interventional radiology rotations. 

“This year at AUA I witnessed an unprecedented interest in image-guided focal ablation for prostate cancer using both HIFU and cryotherapy. The increase in the number of peer-reviewed publications on focal therapy is a strong indicator of a paradigm shift in prostate cancer management,” said Naren Sanghvi, PhD, a senior consultant to the Focused Ultrasound Foundation. “Many discussions took place on the importance of proper patient selection and how it will improve focal therapy treatments. I expect these publications to continue to increase as physicians and hospitals continue to adopt focal therapy programs.” 

Profound Medical and EDAP each issued a press release about their participation in the meeting: 

There were 15 abstracts that may be of interest to the focused ultrasound community, as listed below. All abstracts were published in the Journal of Urology. They can be searched and accessed here

LBA03-07: Imperial Prostate-4 Comparative Healthcare Research Outcomes of Novel Surgery in Prostate Cancer (IP4-CHRONOS): Early Feasibility, Safety, and Functional Outcomes from a Pilot RCT 

MP09-08: Predictive Value of Lacdinac-Glycosylated Prostate Specific Antigen at 3 Months After Focal Therapy with High-Intensity Focused Ultrasound for Detection of Clinically Significant Prostate Cancer During Follow-Up: A Multi-Institutional Study 

MP12-02: Race Reporting in Prostate Cancer Focal Therapy Clinical Trials 

MP73-02: Focal Therapy – 7 Years Experience with Focal High Intensity Focused Ultrasound In 164 Patients with Prostate Cancer: Single Center Results 

MP73-04: External Validation of a Risk Score Predicting Failure After Salvage Focal Therapy for Localized Radiorecurrent Prostate Cancer: An Analysis from the Focal Recurrent Assessment and Salvage Treatment (FORECAST) Trial 

MP73-05: Pivotal Study of MRI-Guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: 4-Year Follow Up 

MP73-08: Focal Ablative Salvage Therapy for Radio-Recurrent Prostate Cancer: A 10 Year Experience of Oncological and Safety Outcomes in 276 Patients 

MP73-09: A Retrospective Clinical Service Evaluation of Lesion-Targeted MRI-Guided Transurethral Ultrasound Ablation (TULSA) for the Treatment of Localized Prostate Cancer 

MP73-13: MRI Analysis of Prostate Morphometry and Periprostatic Anatomical Relationships Before and After Partial High-Intensity Focused Ultrasound Treatment of Localized Prostate Cancer 

MP73-15: Comparison of Postoperative Complications Between Focal Ablation and Radical Prostatectomy for Intermediate-Risk Prostate Cancer: The FARP Randomized Control Trial 

MP73-16: SUV Variation on PSMA PET/CT Correlates with Biochemical Response in Patients with Prostate Cancer Undergoing High-Intensity Focused Ultrasound (HIFU) Focal Therapy 

MP73-17: Whole Gland Ablation Using High-Intensity Focused Ultrasound Versus Robot-Assisted Radical Prostatectomy: A Propensity Score-Matched Study 

MP73-19: Focal Cryoablation vs Focal High Intensity Focused Ultrasound for Intermediate and High-Risk Prostate Cancer 

MP76-10: Transurethral Ultrasound Ablation (TULSA) for Benign Prostatic Obstruction: 12 Months Clinical Outcomes 

V10-10: Novel Technique: Peri-Vesical Fat Rotational Flap for Rectal Interposition Coverage in Salvage Robotic Radical Prostatectomy 

AUA 2024 will be held May 3–6, 2024, in San Antonio, Texas. 

See the Meeting Program